Prescription drug monitoring programs evaluation: A systematic review of reviews.

[1]  L. Karimi,et al.  Mapping the research addressing prescription drug monitoring programs: A scoping review. , 2022, Drug and alcohol review.

[2]  S. Nielsen,et al.  How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis. , 2021, Drug and alcohol dependence.

[3]  M. Asbridge,et al.  Health Care Provider Utilization of Prescription Monitoring Programs: A Systematic Review and Meta-Analysis , 2021, Pain medicine.

[4]  Sue S. Feldman,et al.  Barriers and facilitators to PDMP IS Success in the US: A systematic review. , 2020, Drug and alcohol dependence.

[5]  Stephen G. Henry,et al.  Changes in opioid prescribing after implementation of mandatory registration and proactive reports within California's prescription drug monitoring program. , 2020, Drug and alcohol dependence.

[6]  Norjihan Abdul Ghani,et al.  Prescription drug monitoring programs in the US: A systematic literature review on its strength and weakness. , 2020, Journal of infection and public health.

[7]  Guohua Li,et al.  Prescription Drug Monitoring Programs and Prescription Opioid-Related Outcomes in the United States. , 2020, Epidemiologic reviews.

[8]  M. Asbridge,et al.  Effectiveness of Prescription Monitoring Programs in Reducing Opioid Prescribing, Dispensing, and Use Outcomes: A Systematic Review. , 2019, The journal of pain : official journal of the American Pain Society.

[9]  M. Asbridge,et al.  The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review , 2019, BMC Health Services Research.

[10]  R. McHugh,et al.  The epidemiology of benzodiazepine misuse: A systematic review. , 2019, Drug and alcohol dependence.

[11]  Daniel M. Hartung,et al.  Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review. , 2018, Journal of the American Pharmacists Association : JAPhA.

[12]  Michael Lawrence Barnett,et al.  Patterns of Potential Opioid Misuse and Subsequent Adverse Outcomes in Medicare, 2008 to 2012 , 2018, Annals of Internal Medicine.

[13]  Chris Delcher,et al.  Association Between Prescription Drug Monitoring Programs and Nonfatal and Fatal Drug Overdoses , 2018, Annals of Internal Medicine.

[14]  George E. Higgins,et al.  Strengths and Weaknesses of Prescription Drug Monitoring Programs: A Focus Group Assessment of Law Enforcement Officers , 2018 .

[15]  P. Tugwell,et al.  AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both , 2017, British Medical Journal.

[16]  Chris Delcher,et al.  Law Enforcement Officers’ Perceptions of Florida’s Prescription Drug Monitoring Program , 2017 .

[17]  Donald D. McGeary,et al.  Evaluating the impact of prescription drug monitoring program implementation: a scoping review , 2017, BMC Health Services Research.

[18]  Dhaval M Dave,et al.  Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse , 2017, Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management].

[19]  K. Evoy,et al.  Abuse and Misuse of Pregabalin and Gabapentin , 2017, Drugs.

[20]  R. Hoffman,et al.  A survey of Physicians' Perspectives on the New York State Mandatory Prescription Monitoring Program (ISTOP). , 2016, Journal of substance abuse treatment.

[21]  Linda Rasubala,et al.  Impact of a Mandatory Prescription Drug Monitoring Program on Prescription of Opioid Analgesics by Dentists , 2015, PloS one.

[22]  I. McRae,et al.  An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions , 2014, BMC Pharmacology and Toxicology.

[23]  Laxmaiah Manchikanti,et al.  Opioid epidemic in the United States. , 2012, Pain physician.

[24]  P. Friedmann,et al.  Revisiting Paulozzi et al.'s "Prescription drug monitoring programs and death rates from drug overdose". , 2011, Pain medicine.

[25]  M. Clarke,et al.  Methodology in conducting a systematic review of systematic reviews of healthcare interventions , 2011, BMC medical research methodology.

[26]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[27]  M. Laurant,et al.  Process evaluation on quality improvement interventions , 2003, Quality & safety in health care.

[28]  P. Tugwell,et al.  Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. , 2007, BMC medical research methodology.